Close Menu

NEW YORK (GenomeWeb) – Exact Sciences reported after the close of the market on Monday that its third quarter revenues rose 158 percent year over year, driven by a 136 percent increase in the number of completed Cologuard colon cancer tests.

For the three months ended Sept. 30, the molecular diagnostics company reported revenues of $72.6 million, up from $28.1 million a year earlier, and significantly beating analysts' consensus estimate of $65.0 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.